Related News
Home » Business » Manufacturing
Roche net income decreases 29% in H1
By Alexander G. Higgins |
July 24, 2009, Friday
|
Print Edition
Print Edition
PHARMACEUTICALS maker Roche Holding AG yesterday posted a 29 percent drop in net income for the first six months because of costs related to the takeover of California-based Genentech, but results were boosted by sales of the antiviral Tamiflu in the face of the swine flu pandemic.
Sales of anticancer drugs also fed the profit of 4.1 billion Swiss francs (US$3.84 billion), which compares with 5.7 billion francs in the year-earlier period, Roche said.
Excluding exceptional items, net income attributable to Roche shareholders was up 11 percent at 5.2 billion francs.
The company said Tamiflu sales accounted for 4 percentage points of sales growth in pharmaceuticals.
Group sales were up 2 billion francs, or 9 percent, to 24 billion francs.
"I am especially pleased about the excellent progress we've made in integrating Roche and Genentech," CEO Severin Schwan said. "Work at Genentech's research and early development center in South San Francisco has continued seamlessly with the existing management team."
Schwan said the company would be realizing synergies from the merger sooner than originally anticipated because of the consolidation of the manufacturing network and streamlining administrative functions.
The company said total one-time integration costs would be approximately 3 billion Swiss francs.
The acquisition strengthens Roche's ability to deliver on innovation in its core pharmaceuticals and diagnostics businesses, Schwan said.
Sales of anticancer drugs also fed the profit of 4.1 billion Swiss francs (US$3.84 billion), which compares with 5.7 billion francs in the year-earlier period, Roche said.
Excluding exceptional items, net income attributable to Roche shareholders was up 11 percent at 5.2 billion francs.
The company said Tamiflu sales accounted for 4 percentage points of sales growth in pharmaceuticals.
Group sales were up 2 billion francs, or 9 percent, to 24 billion francs.
"I am especially pleased about the excellent progress we've made in integrating Roche and Genentech," CEO Severin Schwan said. "Work at Genentech's research and early development center in South San Francisco has continued seamlessly with the existing management team."
Schwan said the company would be realizing synergies from the merger sooner than originally anticipated because of the consolidation of the manufacturing network and streamlining administrative functions.
The company said total one-time integration costs would be approximately 3 billion Swiss francs.
The acquisition strengthens Roche's ability to deliver on innovation in its core pharmaceuticals and diagnostics businesses, Schwan said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
